83% of pharma's trials published

More than eight out of 10 pharma-sponsored clinical trials made it into a peer-reviewed journal, a 23% increase over the 2008 rate, researchers showed.

Executives interviewed think the hike is likely driven by more stringent demands for investigators to publish, said research firm Cutting Edge Information.

Drug companies are holding investigators more accountable for publishing to journals, the firm said. Many write publication clauses in contracts, making final milestone payments conditional on publication of trial results.

One drug company no longer accepts proposals from investigators unwilling to agree to write trial data up for publication, Cutting Edge said.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


As US pharma continued its quest for a Grand Prix at the Lions Health international festival of creativity, MM&M went on location to Cannes, France. Missed our coverage from June? Now, we're giving you an opportunity to catch up on some of what you missed. Download our e-book on the two-day festival, recapping the event, rounding up the best of the speakers, offering perspective and listing all of the winners. Click here to download.


The most recent MM&M Skill Sets Live event surveyed a range of issues relating to one of the hottest promotional spaces in healthcare. Speakers and panelists at the morning-long session, including promotional- and multichannel-minded executives from GSK, Epocrates, Treato and Montefiore Medical Center, weighed in on topics designed to help marketers demystify the challenges associated with non-personal promotion. Click here.